poisar

Stocks · News reference

Celcuity shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CELC
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Celcuity Inc. (CELC)

    Filed: 2026-10-02 AccNo: 0001193125-26-411297 Size: 376 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    CELC
  2. Eric Volkman

    Why Celcuity Stock Was a Winner on Wednesday

    Celcuity stock gained 2.8% on Wednesday as the biotech company launched its first FDA-approved drug, Revtorpyk, for HR+/HER2 breast cancer treatment. The company also introduced support services for patients and physicians. The stock outperformed the broader market, which saw the S&P 500 decline 0.3%.

    CELC